Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns. read more
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients